Farberg AS, Jing XL, Monson LA, Donneys A, Tchanque-Fossuo CN, Deshpande SS, Buchman SR, et al.
Bone. Date of publication 2012 May 1;volume 50(5):1184-7.
1. Bone. 2012 May;50(5):1184-7. doi: 10.1016/j.bone.2012.01.019. Epub 2012 Feb 1.
Deferoxamine reverses radiation induced hypovascularity during bone regeneration
and repair in the murine mandible.
Farberg AS(1), Jing XL, Monson LA, Donneys A, Tchanque-Fossuo CN, Deshpande SS,
Buchman SR.
Author information:
(1)Craniofacial Research Laboratory, University of Michigan Medical School, Ann
Arbor, MI 48109-0219, USA. afarberg@umich.edu
BACKGROUND: Deferoxamine (DFO) is an iron-chelating agent that has also been
shown to increase angiogenesis. We hypothesize that the angiogenic properties of
DFO will improve bone regeneration in distraction osteogenesis (DO) after x-ray
radiation therapy (XRT) by restoring the vascularity around the distraction site.
MATERIAL AND METHODS: Three groups of Sprague-Dawley rats underwent distraction
of the left mandible. Two groups received pre-operative fractionated XRT, and one
of these groups was treated with DFO during distraction. After consolidation, the
animals were perfused and imaged with micro-CT to calculate vascular
radiomorphometrics.
RESULTS: Radiation inflicted a severe diminution in the vascular metrics of the
distracted regenerate and consequently led to poor clinical outcome. The DFO
treated group revealed improved DO bone regeneration with a substantial
restoration and proliferation of vascularity.
CONCLUSIONS: This set of experiments quantitatively demonstrates the ability of
DFO to temper the anti-angiogenic effect of XRT in mandibular DO. These exciting
results suggest that DFO may be a viable treatment option aimed at mitigating the
damaging effects of XRT on new bone formation.
Copyright © 2012 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.bone.2012.01.019
PMCID: PMC3322244
PMID: 22314387 [Indexed for MEDLINE]
